Deals
Sanofi will pay Regeneron $582m in deal restructuring
January 7, 2019Sales and Marketing Deals, Regeneron, Sanofi, biotech, pharma
French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal …
AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development
UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million
June 29, 2016Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition
Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …
Bayer offers $62 billion for Monsanto in all cash deal
May 23, 2016Research and Development, Sales and Marketing Bayer, Deals, Financial, Merger & Acquisition, monsanto
German pharma and crop sciences giant Bayer (ETR: BAYN) has made an unsolicited $62 billion all-cash offer for Monsanto Co …
Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing
UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy
March 16, 2016Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development
Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …
Mirror. Signal. Merger. How to deal with a pharma takeover
December 14, 2015Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers
So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …
2015’s top five mergers and acquisitions in a record-breaking year
October 19, 2015Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers
A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …
Hundreds of jobs threatened after big pharma deals close
April 7, 2015Medical Communications, Research and Development, Sales and Marketing Deals, GSK, Jobs, Novartis, US, Valeant, job losses, redundancy, salix
Fresh from deals worth a combined $34 billion, GSK and Salix Pharmaceuticals have announced company restructures that have placed more …
Valeant to buy Salix in $14.5 billion move
February 23, 2015Sales and Marketing Deals, Heptares, Valeant, mergers, salix, sosei
Valeant has agreed a deal to acquire US-based speciality manufacturer of gastrointestinal drugs Salix in a move worth around $14.5 …
AstraZeneca signs MIT/Harvard research deal
September 17, 2012Business Services, Research and Development, Sales and Marketing AstraZeneca, Deals, Havard, MIT
AstraZeneca has signed a two-year collaboration with an academic institution – affiliated to the illustrious universities MIT and Harvard – …
Latest content
FibroFind appoints Lee Borthwick as CEO
